AstraZeneca COVID-19 vaccine Source: EMA Twitter
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australia’s medical regulators are urgently reviewing the latest health advice on AstraZeneca’s COVID-19 immunisation
  • The European Medicines Agency (EMA) has confirmed after weeks of investigation that blood clots, while very rare, are a risk for those taking the vaccine
  • But the E.U. medicines watchdog still said the “overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects”
  • Australia’s Therapeutic Goods Administration (TGA) and Australian Technical Advisory Group on Immunisation (ATAGI) are now reviewing the EMA’s data
  • Prime Minister Scott Morrison said he expects an update from both agencies by Thursday night before the matter will be discussed in national cabinet
  • The U.K. has already announced plans to offer a different COVID-19 vaccine to those under 30, in the wake of the rare blood clot risk being declared

Australia’s medical regulators are urgently reviewing the latest health advice on AstraZeneca’s COVID-19 immunisation.

The European Medicines Agency (EMA) has confirmed after weeks of investigation that blood clots are a very rare risk for those taking the vaccine.

In a statement, the agency said its safety committee “has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects.”

The EMA also advised that “the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.”

Following the European medical watchdog’s announcement, Australia’s Therapeutic Goods Administration (TGA) and Australian Technical Advisory Group on Immunisation (ATAGI) are now reviewing the advice.

Australia’s Prime Minister Scott Morrison said he expects an update from both agencies by Thursday night.

The PM will then discuss the latest information with State and Territory Leaders in Friday’s national cabinet meeting.

Scott Morrison also stated that Australia’s vaccine rollout, which consists primarily of the AstraZeneca jab, will not be changed.

“At this point, there’s no advice to suggest there would be any change to the rollout of the vaccine.”

In the U.K., the government has already begun implementing changes to its vaccine rollout in light of the latest risk update.

The country’s drug regulator also carried out its own, separate review of the AstraZeneca COVID-19 vaccine and found under-30s should be offered a different type of immunisation.

Despite the recommendation though, British Prime Minister Boris Johnson said the AstraZeneca jab was still safe and effective.

The U.K. leader said the vaccine had already saved thousands of lives and will still be used in the country’s vaccination rollout.

More From The Market Online

RBA keeps interest rates on hold in line with expectations

The Reserve Bank of Australia has acted largely in line with expectations and kept Australia's interest…

Aussie unemployment still too low, but Q1 2024 increase tipped: Oxford Economics

The Australian Bureau of Statistics has released unemployment data for October, posting a return to 3.7…

Building Approvals up 7.5 per cent, CapEx also climbs

The number of dwelling approvals rose 7.5 per cent last month, in a big turn around…

Australian unemployment rate remains at 3.9pc despite 65,000 job losses

Australia saw a significant employment drop of 65,000 jobs in December 2023, marking the second-largest loss…